OncoResponse (spinout from Theraclone Sciences) mines the human adaptive immune system to discover therapeutic antibodies against novel immuno-oncology targets.
In Jan 2016, OncoResponse and the Knight Cancer Institute at Oregon Health & Science University collaborate to identify antibodies against novel targets in elite responders to cancer immunotherapy. The agreement provides OncoResponse with access to OHSU patient samples in two cancer indications, prostate cancer and chronic myeloid leukemia (CML), for immune repertoire screening to identify antibodies with exceptional reactivity from patients who have elite responses to cancer immunotherapies.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
OncoResponse, licensed the I-STAR_ platform, developed and validated by Theraclone Sciences, to interrogate the human memory B-cell repertoire of cancer patients who are considered _Elite RespondersÓ to immunotherapy. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
In Nov 2017, OncoResponse acquired Paganini Biopharma, acquiring all of its assets including an anti-epithelial membrane protein 2 (EMP2) fully human monoclonal antibody, ONCR-201. Paganini Biopharma was founded on technology originated in the Department of Pathology and Laboratory Medicine of the School of Medicine at UCLA. Financial terms of the acquisition remains undisclosed.
In March 2017, OncoResponse closed its ongoing $22.5 Mn Series A financing round, with additional investment from existing investors and HT Family Office (HTFO).
In May 2016, OncoResponse completed $12.5 Mn Series A round funding with an investment from Baxalta Inc., ARCH Venture Partners, Canaan Partners, MD Anderson, William Marsh Rice University and Alexandria Real Estate Equities.